trending Market Intelligence /marketintelligence/en/news-insights/trending/iIZvhyisJR5-a8R2HkRc_A2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Aerpio Pharmaceuticals starts review of strategic alternatives

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Aerpio Pharmaceuticals starts review of strategic alternatives

Aerpio Pharmaceuticals Inc. has shuffled its management as it plans to explore strategic alternatives to maximize shareholder value.

According to an Oct. 21 release, the Cincinnati-based company's clinical assets and cash resources totaled $48.2 million as of June 30.

The board is exploring various options, including a possible acquisition, merger, business combination, asset sale, in-license, out-license and the sale of the company's sale.

Evercore, Ladenburg Thalmann & Co. Inc. and Duane Nash will act as strategic advisers to Aerpio for the process.

As the company streamlines operations, President Joseph Gardner will lead Aerpio's management team and Vice President of Finance Gina Marek will retain her current position, while CEO Stephen Hoffman and CFO Michael Rogers have transitioned from their roles. Hoffman also resigned from his position on the board.

The company's stock price rose 19.03% to about 55 cents as of 3:06 p.m. ET on Oct. 21.

Aerpio Pharmaceuticals is a biopharmaceutical company that develops and commercializes treatments for eye-related diseases and disorders. On March 18, the company announced the failure of one of its experimental drugs in improving symptoms of diabetes-related vision loss in a mid-stage study.